Group One Trading’s Aprea Therapeutics APRE Stock Holding History

Group One Trading’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,900	Closed	-$131K	–	6999
2023 Q4	$131K	Hold	27,900	–	–	﹤0.01%	4235
2023 Q3	$117K	Hold	27,900	–	–	﹤0.01%	4308
2023 Q2	$87.9K	Hold	27,900	–	–	﹤0.01%	4743
2023 Q1	$124K	Buy	27,900 +22,990	+468%	+$170K	﹤0.01%	4107
2022 Q4	$31.6K	Sell	4,910 -70	-1%	-$739	﹤0.01%	5309
2022 Q3	$65K	Sell	4,980 -1,120	-18%	-$19.9K	﹤0.01%	5172
2022 Q2	$90K	Buy	6,100 +1,820	+43%	+$42K	﹤0.01%	5076
2022 Q1	$159K	Buy	4,280 +4,035	+1,647%	+$165K	﹤0.01%	5038
2021 Q4	$14K	Sell	245 -635	-72%	-$56.1K	﹤0.01%	7165
2021 Q3	$90K	Sell	880 -1,150	-57%	-$104K	﹤0.01%	6010
2021 Q2	$198K	Buy	2,030 +2,020	+20,200%	+$187K	﹤0.01%	5258
2021 Q1	$1K	Buy	+10	New	+$1.17K	﹤0.01%	7439

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading's APRE Position: Q1 2026 in Review

Group One Trading held its Aprea Therapeutics (APRE) position steady in Q1 2026 at 577 shares worth $440. The position accounts for ﹤0.01% of the portfolio, ranked #7331.

Group One Trading first reported a position in APRE in Q1 2021 and has held it in 21 quarters since. The position peaked at $372K in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Group One Trading held 577 shares of Aprea Therapeutics worth $440 as of Q1 2026.
Group One Trading left its Aprea Therapeutics share count unchanged in Q1 2026.
Aprea Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7331 holding.
Group One Trading first reported a position in Aprea Therapeutics in Q1 2021 and has held it in 21 quarters since.
Group One Trading's Aprea Therapeutics position peaked at $372K in Q3 2021.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.